PSA through primary toxicity endpoint (day 30).
ADENOVIRUS
Ad dose: Adenoviral dose, PSA FU: PSA follow up, T to PreTx: Time (month) before the start of androgen suppression therapy, % PSA decline: PSA decline for each patient within 30 days of oncolytic adenoviral injection; NR: Not reported, NE: Not estimated, AST: Androgen suppression therapy, #: Patient 3 withdrew the consent, although his PSA was still monitored for clinical care it is not reported here.There was no significant effect of adenovirus injection on the PSA doubling time (PSADT) in individual patients (